Gagan Mathur | Medicine and Dentistry Award | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Gagan Mathur | Medicine and Dentistry Award | Best Researcher Award

Assoc Prof Dr. Gagan Mathur, University of California Irvine, United States

Assoc Prof Dr. Gagan Mathur: Candidate for Best Researcher Award Evaluation

Publication profile

Employment History

Dr. Gagan Mathur is a highly experienced professional with a strong background in transfusion medicine and clinical pathology. Since December 2022, he has served as the Medical Director of Transfusion Medicine-Blood Bank at the University of California Irvine School of Medicine, where he also holds the role of Associate Program Director of the Pathology Residency Program. He has previously held prominent positions at the Children’s Hospital Los Angeles and Saint Luke’s Health System in Kansas City, demonstrating his leadership and expertise in managing complex medical and educational settings.

Post-Graduate Training and Education

Dr. Mathur’s rigorous academic background includes a fellowship in Transfusion Medicine/Blood Banking and a residency in Clinical Pathology at the University of Iowa Hospitals & Clinics. He also holds an MBA from the University of Iowa, which complements his medical expertise with business acumen. His foundational medical education was completed at Dr. S.N. Medical College in India.

Certifications and Licensure

Dr. Mathur is board-certified in both Transfusion Medicine/Blood Banking and Clinical Pathology by the American Board of Pathology. He holds medical licenses in California and previously held licenses in Missouri, Kansas, and Iowa. His certification as a Certified Physician Executive underscores his commitment to leadership in healthcare.

Awards and Distinctions

Dr. Mathur has been recognized for his contributions to medicine with numerous accolades, including being named a Top Pathologist by Best in California Magazine in 2023 and a multiple nominee for the Orange County Physician of Excellence award. His early recognition includes the Paul E. Strandjord Young Investigator Award and an Outstanding Reviewer award from a leading scientific journal.

Teaching and Mentoring

Dr. Mathur is actively involved in teaching and mentoring the next generation of medical professionals. He serves as an Associate Program Director and Chair of the Clinical Competency Committee in the Pathology Residency Program at UC Irvine. He also contributes as a faculty member in various transfusion medicine and blood banking courses for medical students, residents, fellows, and clinical laboratory scientist students.

Publication Top Notes

  • Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22 (Journal of Analytical Toxicology) – Cited by 206, 2014 🧪📊
  • Antibody testing for COVID-19: can it be used as a screening tool in areas with low prevalence? (American Journal of Clinical Pathology) – Cited by 90, 2020 🦠🔬
  • High clinical suspicion of donor‐derived disease leads to timely recognition and early intervention to treat solid organ transplant‐transmitted lymphocytic choriomeningitis virus (Transplant Infectious Disease) – Cited by 29, 2017 🏥🦠
  • Use of a data warehouse at an academic medical center for clinical pathology quality improvement, education, and research (Journal of Pathology Informatics) – Cited by 25, 2015 📈🧑‍💻
  • Clinical profile and mortality among novel influenza A (H1N1) infected patients: 2009-2010 Jodhpur, Rajasthan pandemic (Journal of the Association of Physicians of India) – Cited by 25, 2013 🏥🌍
  • Antibody testing for COVID-19 (American Journal of Clinical Pathology) – Cited by 7, 2020 🦠🧬
  • Factors influencing platelet clumping during peripheral blood hematopoietic stem cell collection (Transfusion) – Cited by 7, 2017 🩸🔬
  • A clinico-epidemiologic study of neurologic associations and factors related to speech and language delay (National Journal of Community Medicine) – Cited by 7, 2012 🧠🗣️
  • Solutions to technical challenges during therapeutic plasma exchange using the Spectra Optia on a 4 kilogram neonate (Transfusion and Apheresis Science) – Cited by 5, 2018 🍼🩸
  • Streamlined sign-out of capillary protein electrophoresis using middleware and an open-source macro application (Journal of Pathology Informatics) – Cited by 5, 2014 🧬💻
  • A case for a national registry of red blood cell antibodies (Vox Sanguinis) – Cited by 4, 2022 🩸🧾
  • Predicting changes in hemoglobin S after simple transfusion using complete blood counts (Transfusion) – Cited by 3, 2018 🩸🧪
  • A case cluster of lymphocytic choriomeningitis virus transmitted via organ transplantation (Transplantation) – Cited by 2, 2014 🦠🏥


Conclusion

Assoc Prof Dr. Gagan Mathur’s extensive experience, academic background, and leadership roles make him a strong candidate for the Best Researcher Award. His contributions to transfusion medicine, combined with his teaching and mentoring roles, demonstrate a commitment to advancing medical science and education. His recognition by peers and multiple accolades further support his suitability for this prestigious award

Cristina Papayannidis | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Cristina Papayannidis | Medicine and Dentistry | Best Researcher Award

Dr Cristina Papayannidis, IRCCS, Azienda Ospedaliero Universitaria S.Orsola Malpighi, Bologna, Italy, Italy

Dr. Cristina Papayannidis appears to be an outstanding candidate for the Best Researcher Award based on several key criteria:

Publication profile

scopus

Extensive Experience

Dr. Papayannidis has been deeply involved in clinical research and patient care in hematology since her early career. Her role as Dirigente Medico Ematologia at IRCCS Azienda Ospedaliero Universitaria di Bologna highlights her leadership in AML and ALL clinical trials.

High Research Output

She has authored over 130 publications and has been a principal or sub-investigator in more than 60 phase 1-3 clinical trials, showcasing her significant contributions to advancing hematology research.

Recognition and Influence

With an H-index of 34, she has made substantial impacts in her field. Her role as a speaker at over 300 national and international events, including prestigious conferences like ASH and EHA, underscores her influential presence in the hematological community.

Mentorship and Leadership

Her positions as a mentor in EHA Master Classes and member of various working groups demonstrate her commitment to guiding the next generation of researchers and shaping the future of hematology.

Professional Memberships

  1. Memberships in esteemed organizations such as SIE, EHA, and AACR, and her role on the Hematological Malignancies Committee ESMO further reflect her prominent status and active participation in the scientific community.

Dr. Papayannidis’s extensive research experience, high publication volume, significant impact on clinical practice, and active involvement in mentorship and professional societies make her a highly suitable candidate for the Best Researcher Award.

 

Research focus
The research focus of the individuals associated with these articles centers on hematological malignancies and their management. They investigate advanced treatments and strategies for diseases like acute lymphoblastic leukemia (ALL), particularly in the context of drug therapies and stem cell transplantation. Key topics include evaluating the efficacy of ponatinib versus imatinib in treating Philadelphia chromosome-positive ALL, using ponatinib to prevent relapse after transplantation, and assessing the impact of inotuzumab ozogamicin on outcomes and complications in refractory cases. Their work contributes to improving therapeutic approaches and patient outcomes in hematology. 🩺💉🔬

Publication top notes

Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC)

Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission †

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease

Dan Yan | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dan Yan | Medicine and Dentistry | Best Researcher Award 

Prof Dan Yan,Beijing Friendship Hospital, Capital Medical University,China

Prof. Dan Yan, Ph.D., is a leading figure in clinical pharmacy and precision medicine at Beijing Institute of Clinical Pharmacy, China. 🌟 With a robust background in traditional Chinese medicine and a Ph.D. from Chengdu University, he specializes in intelligent molecular diagnosis and combined medication for chronic metabolic diseases. 🧬 His groundbreaking research focuses on optimizing diabetes treatment, particularly exploring multi-drug combinations and personalized therapies. As a prolific author and committee member of prestigious scientific organizations, Prof. Yan is dedicated to advancing healthcare through innovative research and evidence-based practices. 📚✨

Publication profile

Scopus

Education

Prof. Dan Yan pursued an extensive educational journey at Chengdu University of Traditional Chinese Medicine, culminating in a Ph.D. from 2004 to 2007. Prior to his doctoral studies, he obtained his Master of Science degree from the same institution between 2001 and 2004. Prof. Yan’s academic pursuits trace back to his undergraduate years, where he completed his Bachelor of Science degree from 1994 to 1998, laying the foundation for his subsequent advanced studies. His educational background reflects a dedicated commitment to traditional Chinese medicine, fostering a deep expertise in this field.

Research focus

Prof. Dan Yan’s research focuses on the intelligent molecular diagnosis and combined medication for chronic metabolic diseases, particularly pre-diabetes and type 2 diabetes. His work leverages multi-omics approaches, such as metabolomics, to enhance early diagnosis and personalized treatment strategies. He aims to optimize drug combinations from a broad range of hypoglycemic drugs, including traditional and novel therapies. This research not only addresses the declining efficacy of long-term metformin use but also integrates pharmacoeconomics and evidence-based medicine to improve clinical outcomes in diabetes care.

 

Publication top notes

Structural characterization of Astragalus polysaccharide-D1 and its improvement of low-dose metformin effect by enriching Staphylococcus lentus

A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: Whether a specific approach is justified to tackle the challenges?

Antibiotic combinations prediction based on machine learning to multicentre clinical data and drug interaction correlation

Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation

Rapid multichannel fluorescent probe assay for CYP450 inhibition screening and drug interaction monitoring

QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment

β-Elemene in zedoary turmeric oil injection induces dyspnea by binding to hemoglobin and upregulating HIF-1α

Predicting coronary heart disease in Chinese diabetics using machine learning

Editorial: Benefits and risks of drug combination therapy for chronic metabolic diseases

Quality assessment and control of Shuanghuanglian Lyophilized Injection based on cell response spectrum